On 6 October, the European Court of Justice (‘ECJ’) issued another “score draw” judgment  in the long-running battle of R&D-based pharmaceutical companies to limit parallel trade in medicines across the EU. While the ECJ required the European Commission to conduct an in-depth examination of whether EU competition rules can be declared inapplicable to GlaxoSmithKline’s Spanish general sales conditions, it also confirmed that an agreement limiting parallel trade is a restriction of competition “by object”. Provided pharmaceutical companies can put forward cogent evidence of appreciable efficiencies, the need to conduct a full investigation into whether an exemption is available is unlikely
The EU Court of Justice confirms that the Commission must assess whether an agreement to limit parallel trade in medicines has pro-competitive benefits (GlaxoSmithKline)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.